Published in Clinical Cancer Research · View the paper (DOI)
Researchers confirm that fibrosis in HER2-negative breast tumors is associated with an adverse prognosis and better treatment outcomes with nintedanib. A new test, MeCo Score, analyzes gene activity related to fibrosis and indicates the effectiveness of supplementing chemotherapy with antifibrotic therapy.
Coverage from 2 institutions